# DESCRIPTION

## BACKGROUND

- define glycogen storage disease type 1
- describe GSD-Ia symptoms and complications
- highlight limitations of current treatments

## SUMMARY

- introduce mRNA therapeutics for GSD-Ia treatment
- describe mRNA encoding G6PC with modified nucleotides
- outline LNP delivery system for mRNA
- summarize pharmaceutical composition with mRNA and LNP
- describe administration methods and dosages
- outline therapeutic effects on G6PC activity and glycogen levels
- describe reduction of liver glycogen and G6P levels
- outline reduction of serum triglycerides
- describe increase in blood glucose levels
- summarize pharmaceutical composition with delivery agent
- describe G6PC polypeptide sequence and ORF identity
- outline mRNA with microRNA binding site and 3' UTR sequence
- define mRNA structure
- describe 5' UTR
- describe 5' terminal cap
- describe poly-A region
- describe chemically modified nucleobases
- describe human subject conditions
- define polynucleotide structure
- describe ORF sequence identity
- describe stop codon
- describe 3' UTR
- describe miR binding site
- describe miR binding site location
- describe 3' UTR sequence identity
- define mRNA structure
- describe 5' UTR
- describe 3' UTR
- describe poly-A region
- describe chemically modified nucleobases
- describe polynucleotide sequences
- describe pharmaceutical composition
- describe delivery agent
- describe method of expressing G6PC polypeptide
- describe method of treating GSD-Ia
- describe method of increasing glucose blood level
- describe method of reducing liver glycogen level
- describe method of reducing serum triglyceride level
- describe method of increasing G6PC activity

## DETAILED DESCRIPTION

- introduce GSD-Ia disease
- motivate mRNA therapeutics for GSD-Ia treatment
- limitations of mRNA therapeutics
- embodiment of mRNA therapeutic technology

### 1. Glucose-6-Phosphatase (G6PC)

- define G6PC enzyme
- describe G6PC protein structure
- summarize G6PC mutations in GSD-Ia patients
- application of G6PC polypeptides in mRNA therapeutics

### 2. Polynucleotides and Open Reading Frames (ORFs)

- introduce polynucleotides for GSD-I treatment
- define G6PC polypeptides and variants
- describe polynucleotides encoding G6PC polypeptides
- specify sequence-optimized polynucleotides
- describe polynucleotides with codon-optimized ORFs
- introduce mutant G6PC polypeptides with altered activity
- describe polynucleotides encoding functional G6PC fragments
- define polynucleotides
- describe G6PC fragments
- specify G6PC enzymatic activity
- describe ORF encoding G6PC polypeptide
- specify sequence identity to SEQ ID NOs
- describe nucleotide sequence length
- describe noncoding nucleic acid sequences
- describe 5'-UTR and 3'-UTR sequences
- specify polynucleotide composition
- describe poly-A-tail region
- describe delivery agents
- specify mRNA composition

### 3. Signal Sequences

- describe signal sequences for protein trafficking

### 4. Fusion Proteins

- describe fusion proteins with multiple ORFs

### Linkers and Cleavable Peptides

- introduce linkers and cleavable peptides
- describe 2A peptides and their use
- provide examples of 2A peptides
- describe use of 2A peptides for protein separation

### 5. Sequence Optimization of Nucleotide Sequence Encoding a G6PC Polypeptide

- introduce sequence optimization
- describe codon optimization methods
- provide examples of sequence optimization tools
- describe benefits of sequence optimization
- describe sequence optimization for human subjects
- provide methods for sequence optimization
- describe features of sequence-optimized nucleotide sequences

### 6. Sequence-Optimized Nucleotide Sequences Encoding G6PC Polypeptides

- introduce sequence-optimized nucleotide sequences
- provide examples of sequence-optimized G6PC sequences
- describe structure of sequence-optimized polynucleotides
- describe modifications to uracil or thymine content
- describe methods for optimizing codon usage

### 7. Characterization of Sequence Optimized Nucleic Acids

- test sequence optimized nucleic acids
- define expression property
- evaluate sequence optimized nucleic acids functionally
- optimize nucleic acid sequence intrinsic properties
- optimize nucleic acid sequence for protein expression
- optimize target tissue or target cell viability
- reduce immune and/or inflammatory response

### 8. Modified Nucleotide Sequences Encoding G6PC Polypeptides

- define modified nucleotide sequences
- introduce uracil-modified sequences
- describe modified uridine
- specify uracil content
- describe adjusted uracil content
- introduce G/C content adjustment
- describe codon substitution
- specify alternative codon frequency
- describe expression levels
- specify mammalian cell types
- describe administration methods
- specify expression level increases
- describe mRNA stability
- specify stability measurements
- describe immune response reduction
- specify innate immune response reduction
- describe cell death reduction
- specify cell types for immune response reduction
- describe mRNA structure modification
- specify nucleoside and nucleotide modifications
- describe therapeutic compositions
- specify modified nucleotides and nucleosides
- define modified nucleotide sequences
- describe embodiments of RNA nucleic acids
- specify uniform modification of nucleic acids
- describe percentage of modified nucleotides
- introduce untranslated regions (UTRs)
- describe cis-acting RNA elements
- discuss internal ribosome entry sequences (IRES)
- describe upstream open reading frames (uORFs)
- introduce modified polynucleotides with functional RNA elements
- describe desired translational regulatory activities
- define modified nucleotide sequences
- describe RNA elements with desired translational regulatory activity
- identify RNA elements by primary sequence, secondary structure, location, or biological function
- provide mRNA with structural modifications inhibiting leaky scanning
- describe GC-rich RNA elements with specific sequence compositions
- specify location of GC-rich RNA elements relative to Kozak consensus sequence
- provide GC-rich RNA elements with repeating GC-motifs
- describe modified mRNA with GC-rich RNA elements from Table 2
- specify location of GC-rich RNA elements from Table 2 relative to Kozak consensus sequence
- provide examples of GC-rich RNA elements, including V1, V2, and EK
- describe 5' UTR sequences with GC-rich RNA elements
- provide specific embodiments of modified mRNA with GC-rich RNA elements
- define modified mRNA
- describe GC-rich RNA element
- specify location of stable RNA secondary structure
- describe ribosome profiling technique
- explain role of UTRs in translation initiation
- describe features of natural 5'UTRs
- discuss engineering UTRs for enhanced expression
- provide examples of UTRs from various sources
- describe selection of UTRs from families of transcripts
- discuss heterologous UTRs
- provide list of exemplary UTRs
- describe variants of UTRs
- discuss synthetic UTRs
- describe multiple UTRs
- introduce microRNA binding sites
- define modified nucleotide sequences
- introduce sensor sequences
- describe miRNA binding sites
- explain miRNA-mediated regulation
- detail miRNA processing
- define miRNA binding site complementarity
- describe miRNA binding site variations
- explain miRNA binding site function
- discuss advantages of miRNA binding sites
- provide examples of miRNA binding site applications
- introduce miRNA regulation
- describe miRNA expression patterns
- motivate immune cell specific miRNAs
- describe miR-142 binding site engineering
- describe further negative regulatory elements
- list immune cell specific miRNAs
- describe liver specific miRNAs
- describe lung specific miRNAs
- describe heart specific miRNAs
- describe nervous system specific miRNAs
- describe pancreas specific miRNAs
- describe kidney and muscle specific miRNAs
- list miRNAs in endothelial cells
- list miRNAs in epithelial cells
- list miRNAs in embryonic stem cells
- select miRNAs based on expression in immune cells
- describe miRNAs in hematopoietic cells
- describe miRNAs in B cells
- describe miRNAs in progenitor hematopoietic cells
- incorporate multiple miR binding sites
- target multiple cell types with miRs
- modulate immune responses with miRs
- reduce immune cell activation with miRs
- reduce anti-drug antibody response with miRs
- modulate accelerated blood clearance with miRs
- design miR binding sequences
- define modified nucleotide sequences
- describe miRNA binding sites
- motivate auxotrophic polynucleotides
- specify miRNA binding site sequences
- describe insertion of miRNA binding sites
- specify insertion sites for miRNA binding sites
- describe miRNA binding site positioning
- specify codon optimized open reading frames
- describe 3' UTR and 5' UTR structures
- specify multiple miRNA binding sites
- describe polynucleotide composition
- define miRNA binding sites
- specify miR-142-3p binding site
- specify miR-126 binding site
- list non-limiting exemplary miR sequences
- describe miRNA gene regulation
- discuss influence of 5'UTR on miRNA mediated gene regulation
- describe engineering of miRNA binding sites into 3'UTR
- specify possible locations of miRNA binding sites in 3'UTR
- describe control of polynucleotide expression using miRNA binding sites
- discuss targeted expression in specific tissues or cell types
- describe design of miRNA binding sites with varying identity to miRNA seed sequences
- define 3'UTRs
- specify 3'UTR sequences
- describe function of 3'UTRs
- describe 5' cap regions
- introduce modified nucleotide sequences
- describe cap moiety incorporation
- explain non-hydrolyzable cap structure
- describe modified guanosine nucleotides
- introduce cap analogs
- describe limitations of cap analogs
- describe post-manufacture capping
- introduce more authentic 5′cap structures
- describe poly-A tails
- explain polyadenylation process
- describe terminal groups on poly-A tails
- introduce alternative polyA tail structures
- describe unique poly-A tail lengths
- introduce start codon region
- describe alternative start codons
- explain masking agents near start codon
- describe modified nucleotide sequences
- define stop codon region
- outline polynucleotide structure
- provide exemplary G6PC nucleotide constructs
- list specific SEQ ID NOs
- define modified nucleotide sequences
- describe polynucleotide constructs
- specify uracil replacements
- outline polynucleotide composition
- provide methods of making polynucleotides
- introduce modified nucleotide sequences
- describe in vitro transcription/enzymatic synthesis
- motivate RNA polymerase selection
- describe RNA polymerase variants
- discuss polynucleotide or nucleic acid synthesis reactions
- describe DNA polymerase selection
- discuss Syn5 RNA polymerase
- describe chemical synthesis of polynucleotides
- discuss purification of polynucleotides
- define purification of polynucleotides
- describe column chromatography purification
- discuss effects of RP-HPLC purification on G6PC protein expression
- discuss effects of RP-HPLC purification on functional G6PC protein expression
- discuss effects of RP-HPLC purification on detectable G6PC activity
- quantify polynucleotides
- isolate exosomes
- analyze polynucleotides
- correlate with clinical phenotypes
- isolate polynucleotides
- quantify polynucleotides using UV/Vis
- check degradation of polynucleotides
- provide pharmaceutical compositions
- formulate polynucleotides
- prepare pharmaceutical compositions
- package pharmaceutical compositions
- describe pharmaceutical formulations
- formulate polynucleotides with excipients
- describe delivery agents
- provide pharmaceutical formulations
- introduce lipid compounds
- describe delivery agents
- outline lipid nanoparticle formulations
- specify molar ratios of lipid components
- define ionizable lipids
- describe compounds of Formula (I)
- specify subsets of compounds of Formula (I)
- describe compounds of Formula (IA) and (IB)
- describe compounds of Formula (II)
- define modified nucleotide sequences
- describe compounds of Formula (IId) and (IIg)
- describe ionizable lipids
- describe compounds of Formula (III)
- describe phospholipids
- describe phospholipid moieties
- describe fatty acid moieties
- describe functionalized phospholipids
- describe phospholipid analogs and variants
- define modified nucleotide sequences
- describe phospholipid head modifications
- describe phospholipid tail modifications
- describe alternative lipids
- describe structural lipids
- describe polyethylene glycol (PEG)-lipids
- describe PEG-lipid synthesis
- describe PEG-modified lipids
- describe PEG-DMG structure
- describe PEG-OH lipids
- describe compounds of Formula (V)
- describe Formula (V) components
- describe Formula (V) variables
- define modified nucleotide sequences
- specify PEG lipid compounds
- describe lipid compositions
- provide embodiments of LNPs
- define lipid nanoparticle composition
- describe alternative lipid composition
- specify N:P ratio of lipid nanoparticle
- specify wt/wt ratio of ionizable cationic lipid to RNA
- describe mean diameter of lipid nanoparticle
- define alkyl, alkenyl, and alkynyl groups
- define carbocycle and heterocycle groups
- define biodegradable group
- describe optional substituents for alkyl, alkenyl, and cyclyl groups
- describe conversion of nitrogen-containing compounds to N-oxides
- describe other lipid composition components
- specify ratio of lipid composition to polynucleotide
- describe pharmaceutical composition with multiple polynucleotides
- describe lipid:polynucleotide weight ratio
- describe nanoparticle compositions
- define nanoparticle compositions
- describe lipid bilayer structure
- list types of lipid bilayers
- describe ionizable lipids
- define charged moieties
- describe methods for characterizing nanoparticle compositions
- discuss size of nanoparticles
- describe polydispersity index
- discuss zeta potential
- define encapsulation efficiency
- describe methods for measuring encapsulation efficiency
- discuss amount of polynucleotide in nanoparticle composition
- describe N:P ratio
- discuss optimization of N:P ratio
- describe methods for producing lipid nanoparticles
- introduce delivery agents
- describe liposomes
- discuss liposome design
- explain liposome formation
- describe cationic oil-in-water emulsion
- describe water-in-oil emulsion
- describe lipid-polycation complex
- describe lipid nanoparticle formulations
- list ionizable lipids
- describe phospholipids
- describe structural lipids
- describe PEG-modified lipids
- describe LNP formulations
- motivate phosphate conjugates
- summarize polymer conjugates
- describe carbohydrate carriers
- motivate surfactant coatings
- describe mucus-penetrating LNPs
- summarize surface-altering agents
- describe hypotonic formulations
- motivate lipoplex formulations
- describe controlled release and targeted delivery
- describe lipid nanoparticles
- formulate polynucleotides in lipid nanoparticles
- describe geometrically engineered particles
- describe stealth nanoparticles
- formulate polynucleotides with lipidoids
- describe lipidoid synthesis
- test lipidoid formulations
- formulate polynucleotides with aminoalcohol lipidoids
- describe hyaluronidase
- formulate polynucleotides with hyaluronidase
- describe nanoparticle mimics
- formulate polynucleotides in nanoparticle mimics
- describe self-assembled nanoparticles
- formulate polynucleotides in self-assembled nanoparticles
- describe cations and anions
- formulate polynucleotides with cations and anions
- describe modified mRNA formulation
- introduce PLGA microspheres
- describe EVAc polymers
- describe Poloxamer F-407 NF
- formulate polynucleotides with PEG grafted PLL
- formulate polynucleotides with block copolymers
- formulate polynucleotides with amine-containing polymers
- formulate polynucleotides with biodegradable cationic lipopolymer
- formulate polynucleotides with cyclodextrin polymer
- formulate polynucleotides with crosslinked cation-binding polymers
- formulate polynucleotides with PEGylated albumin polymer
- describe nanoparticle formulation
- describe core-shell nanoparticles
- formulate polynucleotides with peptides and proteins
- describe conjugates with carrier or targeting groups
- describe conjugates with naturally occurring substances
- describe conjugates with synthetic molecules
- describe synergistic biomolecule-polymer conjugates
- describe aptamer conjugates
- describe accelerated blood clearance
- introduce immune response to lipid nanoparticles
- describe effectors produced by immune cells
- explain role of B1a and B1b cells in immune response
- describe conventional B cells and their response
- motivate need to inhibit immune response
- describe methods to inhibit immune response
- introduce B1a inert compounds and compositions
- introduce CD19 inert compounds and compositions
- describe compounds and compositions that do not promote ABC
- explain importance of lipid-comprising compounds and compositions
- describe compositions that do not stimulate acute phase response
- describe characteristics of B1a cells
- describe characteristics of B1b cells
- motivate need to block B1a and/or B1b cell activation
- describe strategies to block B1a and/or B1b cell activation
- describe role of pDC cells in ABC and toxicity
- describe role of platelets in ABC and toxicity
- introduce assays to measure ABC activity and related activities
- introduce LNP binding/association to B cells
- describe LNP uptake/internalization by B cells
- motivate LNP compositions evading recognition by ABC
- describe methods of use for reducing ABC
- define LNP that does not promote ABC
- describe relative reduction in activation or induction
- introduce platelet effects and toxicity
- describe coagulopathy and DIC
- describe CARPA and acute phase response
- describe platelet effects and LNP association
- motivate polynucleotides for treating G6PC-related diseases
- describe methods of use for reducing glycogen levels
- describe methods of use for increasing glucose levels
- describe administration of polynucleotides encoding G6PC
- describe reduction in glucose-6-phosphate levels
- describe increase in blood glucose homeostasis
- describe alleviation of GSD-Ia symptoms
- describe reduction in biomarkers of GSD-Ia
- describe increase in biomarkers of GSD-Ia
- motivate gene replacement therapy for GSD-Ia
- describe sequence-optimized polynucleotides
- describe administration of polynucleotides for treating GSD-Ia
- introduce modified nucleotide sequences encoding G6PC polypeptides
- describe administration of cells to mammalian subjects
- detail pharmaceutical compositions and formulations
- describe delivery agents and their mole ratios
- discuss therapeutic effectiveness of drug or treatment
- describe GSD-Ia disease characteristics
- introduce G6PC protein expression levels
- describe measurement of G6PC protein expression levels
- detail exemplary methods for determining protein levels
- describe expected results of mRNA therapy on G6PC protein expression levels
- introduce G6PC protein activity
- describe measurement of G6PC protein activity
- detail exemplary methods for determining enzymatic activity levels
- describe expected results of mRNA therapy on G6PC protein activity
- introduce GSD-Ia biomarkers
- describe determining levels of biomarkers
- discuss comparing biomarker levels
- define terms
- describe reference levels
- motivate biomarkers for GSD-Ia
- describe biomarker levels
- compare biomarker levels
- describe reduction of biomarker levels
- describe sustained reduction of biomarker levels
- describe increase of biomarker levels
- describe sustained increase of biomarker levels
- describe mRNA therapy dosing
- describe liver size as biomarker
- describe biomarker measurement in fasting subjects
- introduce compositions and formulations
- define modified nucleotide sequences
- describe composition and formulation
- specify uracil or thymine content
- outline forms of administration
- list routes of administration
- describe delivery agents
- specify administration methods
- outline pharmaceutical compositions
- describe inactive ingredients
- outline injectable preparations
- describe sterile formulations
- outline kits for protein production
- describe kit components
- outline devices for administration
- describe multi-administration devices
- outline methods and devices utilizing catheters, lumens, and electrical current
- define modified nucleotide sequences encoding G6PC polypeptides
- introduce methods and devices for delivering polynucleotides
- define terms used in the application
- explain singular and plural forms of terms
- define "and/or" and its usage
- specify default meanings of technical and scientific terms
- define "comprising" and its variations
- explain units, prefixes, and symbols
- define numeric ranges and their inclusivity
- explain combinations of elements and their exclusions
- define nucleotides and their notation
- define amino acids and their notation
- explain "about" and its usage
- define "administered in combination" and its variations
- explain amino acid substitution and its notation
- define various terms used in the application
- define conservative amino acid substitution
- define non-conservative amino acid substitution
- define conserved
- define controlled release
- define cyclic or cyclized
- define cytotoxic
- define delivering
- define delivery agent
- define destabilized
- define diastereomer
- define digest
- define distal
- define domain
- define various terms related to polynucleotides and proteins
- define G6PC enzymatic activity
- define helper lipid
- define homology
- define identity
- describe calculation of percent identity
- describe software for sequence alignment
- describe immune response
- define inflammatory response
- define inflammatory cytokines
- define in vitro
- define in vivo
- define insertional and deletional variants
- define intact
- define ionizable amino lipid
- define isolated
- define substantially isolated
- define isomer
- define linker
- define nucleic acid
- define nucleotide sequence encoding
- define off-target
- define open reading frame
- define operably linked
- define optionally substituted
- define part of polynucleotide
- define patient
- define pharmaceutically acceptable
- define pharmaceutically acceptable excipients
- define pharmaceutically acceptable salts
- define pharmaceutically acceptable solvate
- define pharmacokinetic
- define physicochemical
- define polynucleotide
- define polypeptide
- define polypeptide variant
- define polypeptide per unit drug
- define various terms related to disease and treatment
- define reference nucleic acid sequence
- describe salts
- define sample
- explain signal sequence
- describe signal transduction pathway
- define similarity
- explain single unit dose
- describe split dose
- define specific delivery
- explain stable
- describe stabilized
- define stereoisomer
- explain subject
- describe substantially
- define sustained release
- define transfection
- define treating, treatment, therapy
- define unmodified
- define uracil
- define uridine content
- define uridine-modified sequence
- define high uridine codon
- define uridine enriched
- define uridine rarefied
- define variant
- define initiation codon
- describe translation initiation
- define Kozak sequence
- define modified
- define nucleobase
- define nucleoside/nucleotide
- define nucleic acid
- define nucleic acid structure
- define open reading frame
- define RNA element

## CONSTRUCT SEQUENCES

- define G5

## EXAMPLES

### Example 1

- describe triphosphate route for chimeric polynucleotide synthesis
- describe synthetic route for chimeric polynucleotide synthesis

### Example 2

- describe PCR procedure for cDNA production

### Example 3

- describe in vitro transcription reaction for polynucleotide synthesis

### Example 4

- describe enzymatic capping of polynucleotide

### Example 5

- describe polyA tailing reaction for polynucleotide

### Example 6

- describe natural 5′ caps and 5′ cap analogues for polynucleotide synthesis

### Example 7

- describe capping assays for polynucleotide analysis
- describe methods for evaluating capping reaction efficiency

### Example 8

- describe agarose gel electrophoresis for modified RNA or RT PCR products

### Example 9

- introduce Nanodrop UV absorbance readings
- quantify yield of polynucleotides
- describe TE buffer usage
- formulate modified mRNA using lipidoids
- describe in vitro experiment setup
- introduce electrospray ionization
- analyze biological samples
- compare protein fragments to known controls
- introduce matrix-assisted laser desorption/ionization
- analyze biological samples
- compare protein fragments to known controls
- introduce liquid chromatography-mass spectrometry-mass spectrometry
- analyze biological samples
- compare protein fragments to known controls
- synthesize mRNA encoding G6PC
- characterize mRNA sequence
- describe mRNA modification process
- introduce G6Pase activity testing
- test G6Pase activity of individual G6PC substitutions
- analyze effect of S298C substitution on G6Pase activity
- examine effect of Q139R and Q247R substitutions on G6Pase activity
- codon optimize mRNA constructs
- test G6Pase activity of codon optimized mRNA constructs
- select codon optimized mRNA constructs for further study
- introduce in vivo expression and activity of mRNA-encoded G6PC variants
- test G6Pase activity of codon optimized mRNA constructs in vivo
- analyze G6PC protein expression in vivo
- assess duration of action of mRNA-encoded G6PC in a liver-specific knockout mouse model
- test effect of mRNA-encoded G6PC on fasting blood glucose levels
- analyze time course effect of mRNA-encoded G6PC on fasting blood glucose levels
- assess dose response of mRNA-encoded G6PC in a liver-specific knockout mouse model
- test effect of mRNA-encoded G6PC on fasting glucose levels at different doses
- analyze liver weight and appearance after mRNA-encoded G6PC injection
- examine effect of mRNA-encoded G6PC on hepatic glucose-6 phosphate and glycogen levels
- analyze effect of mRNA-encoded G6PC on serum triglyceride and ALT levels
- summarize results of mRNA-encoded G6PC injection in liver-specific knockout mouse model
- show effects of mRNA encoding G6PC on serum lactate levels
- show effects of mRNA encoding G6PC on liver lactate levels
- show hepatic G6Pase activity and G6PC protein expression
- conduct pharmacokinetic analysis of mRNA-encoded G6PC variants
- analyze mRNA levels, protein expression, and G6PC activity over time
- compare protein expression and G6PC activity between G6PC variants
- assess sustained efficacy of mRNA-encoded G6PC in a liver-specific knockout mouse model
- measure fed and fasting glucose levels after multiple injections
- analyze liver weight and G6PC activity after multiple injections
- test efficacy of different lipid nanoparticle formulations
- measure blood glucose levels after injection of mRNA-encoded G6PC
- test impact of miRNA-142 target sites on mRNA-encoded G6PC expression
- analyze protein expression levels in liver and spleen samples
- test in vitro expression of mRNA-encoded G6Pase in kidney cells

